Belite Bio (BLTE) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Regulatory progress and approval timelines

• FDA priority review is underway for Tinlarebant in Stargardt disease, with constructive engagement and updates to be provided as confirmable milestones are reached.

• Japan's Sakigake designation enables a fast-track review, with approval expected close to the FDA's PDUFA date; Japanese regulatory requirements included PK/PD data from local patients, which matched global results.

• Conditional approval in Japan will rely on DRAGON1 data, supplemented by ongoing data from Japanese patients in DRAGON2.

Clinical trial design and efficacy data

• The DRAGON trial used DDAF (definite decreased autofluorescence) as the primary endpoint, validated through the ProgStar natural history study.

• Tinlarebant demonstrated a 36% reduction in lesion growth, with similar efficacy signals in both DDAF and DAF (decreased autofluorescence) measures.

• Fellow eye analysis and supplementation with ProgStar natural history controls strengthened statistical significance and reduced standard error.

• Quantitative autofluorescence confirmed the drug's mechanism of action, though it lacks direct clinical relevance.

• OCT imaging was less optimal due to baseline defects exceeding imaging windows.

Competitive landscape and differentiation

• Recent competitor activity includes Alkeus' phase III program, but Tinlarebant is ahead in development.

• Safety concerns were noted in the Alkeus program, including a severe adverse reaction (intracranial pressure) at high vitamin A doses.

• Efficacy in the Alkeus trial was lower (14%) compared to Tinlarebant's 36% in DRAGON.